Geron Corporation (GERN)
Largest Insider Buys in Sector
GERN Stock Price History Chart
GERN Stock Performance
About Geron Corporation
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is …
Insider Activity of Geron Corporation
Over the last 12 months, insiders at Geron Corporation have bought $0 and sold $8.9M worth of Geron Corporation stock.
On average, over the past 5 years, insiders at Geron Corporation have bought $34,147 and sold $7.78M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 13,186 shares for transaction amount of $30,064 was made by O'Farrell Elizabeth G. (director) on 2023‑08‑24.
List of Insider Buy and Sell Transactions, Geron Corporation
| 2024-07-08 | Sale | EVP, Chief Operating Officer | 674,348 0.1164% | $4.56 | $3.07M | 0.00% | ||
| 2024-06-10 | Sale | EVP, Corp Strategy & CCO | 421,875 0.0656% | $4.64 | $1.96M | -14.09% | ||
| 2024-06-10 | Sale | EVP, Chief Medical Officer | 287,900 0.0446% | $4.63 | $1.33M | -14.09% | ||
| 2024-06-04 | Sale | Chairman, President and CEO | 600,000 0.1014% | $4.00 | $2.4M | +8.79% | ||
| 2024-05-15 | Sale | director | 35,000 0.0057% | $3.75 | $131,250 | +9.87% | ||
| 2023-08-24 | director | 13,186 0.0022% | $2.28 | $30,064 | -4.65% | |||
| 2023-05-11 | Sale | director | 35,000 0.0067% | $3.00 | $105,000 | -20.42% | ||
| 2023-05-01 | Sale | director | 35,000 0.0062% | $2.48 | $86,800 | -10.16% | ||
| 2023-02-10 | Sale | Chairman, President and CEO | 446,668 0.0818% | $3.00 | $1.34M | -23.26% | ||
| 2023-02-09 | Sale | Chairman, President and CEO | 446,666 0.0826% | $3.03 | $1.35M | -22.92% | ||
| 2023-02-09 | Sale | EVP, Chief Operating Officer | 384,719 0.0711% | $3.03 | $1.17M | -22.92% | ||
| 2023-02-08 | Sale | EVP, Chief Financial Officer | 400,000 0.0742% | $3.08 | $1.23M | -23.44% | ||
| 2023-02-08 | Sale | Chairman, President and CEO | 446,666 0.0828% | $3.08 | $1.38M | -23.44% | ||
| 2020-08-21 | director | 17,441 0.0056% | $1.73 | $30,173 | 0.00% | |||
| 2020-01-10 | director | 6,000 0.0029% | $1.34 | $8,056 | +23.36% | |||
| 2019-04-09 | Sale | EVP, Chief Business Officer | 241,270 0.1421% | $2.00 | $482,540 | -23.08% | ||
| 2018-09-13 | Sale | director | 70,000 0.046% | $6.85 | $479,500 | -73.67% | ||
| 2018-08-24 | Sale | EVP, Genl Counsel & Secretary | 75,000 0.0354% | $4.51 | $338,250 | -70.71% | ||
| 2015-05-29 | Sale | EVP BD and Port&Alliance Mgmt | 4,760 0.003% | $3.84 | $18,278 | -14.77% | ||
| 2015-05-29 | Sale | EVP, Chief Financial Officer | 4,760 0.003% | $3.84 | $18,278 | -14.77% |
Insider Historical Profitability
| SCARLETT JOHN A | Chairman, President and CEO | 600000 0.0993% | $3.30 | 2 | 4 | <0.0001% |
| KILEY THOMAS | director | 314059 0.052% | $3.30 | 2 | 0 | <0.0001% |
| BRADBURY DANIEL | director | 142776 0.0236% | $3.30 | 1 | 0 | +67.22% |
| O'Farrell Elizabeth G. | director | 26220 0.0043% | $3.30 | 3 | 0 | +11.68% |
Institutional Investor Ownership
| RA Capital Management, L.P. | $152.47M | 7.79 | 46.2M | 0% | +$0 | 0.15 | |
| BlackRock | $136.67M | 6.98 | 41.41M | -1.8% | -$2.5M | <0.01 | |
| State Street | $104.29M | 5.33 | 31.6M | +23.33% | +$19.73M | <0.01 | |
| Deep Track Capital Lp | $100.67M | 5.14 | 30.51M | +3.12% | +$3.04M | 0.46 | |
| The Vanguard Group | $98.57M | 5.04 | 29.87M | +4.57% | +$4.31M | <0.01 |